Intermittent drug techniques for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 7, 2013, Pages

  Sampson, Stephanie ^a   Mansour, Mouhamad ^b   Maayan, Nicola ^c   Soares Weiser, Karla ^c   Adams, Clive E ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b HENRY FORD HOSPITAL   (United States)

^c Enhance Reviews Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PROCHLORPERAZINE; RISPERIDONE; TRIFLUOPERAZINE;

ADVERSE OUTCOME; AKATHISIA; CLINICAL EFFECTIVENESS; DRUG INTERMITTENT THERAPY; EARLY INTERVENTION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; MAINTENANCE THERAPY; NEUROPSYCHOLOGICAL TEST; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCHIZOPHRENIA; SOCIAL STATUS; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREATMENT RESPONSE; DISEASE COURSE; DRUG ADMINISTRATION; HOSPITALIZATION; MAINTENANCE CHEMOTHERAPY; META ANALYSIS; MOVEMENT DISORDERS; PROCEDURES; RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA;

ANTIPSYCHOTIC AGENTS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HOSPITALIZATION; HUMANS; MAINTENANCE CHEMOTHERAPY; MOVEMENT DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SCHIZOPHRENIA;

EID: 84883013788     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006196.pub2     Document Type: Review

References (135)

1. Blackburn HL, Allen JL. Behavioural effects on interrupting and resuming tranquillizing medication among schizophrenics. Journal of Nervous and Mental Disease 1961;133(4):303-8.
2. Caffey EM, Diamond LS, Frank TV, Grasberger JC, Herman L, Klett CJ, et al. Discontinuation or reduction of chemotherapy in chronic schizophrenics. Journal of Chronic Diseases 1964;17(4):347-58.
3. Carpenter WT, Heinrichs DW. Early intervention, time limited, targeted pharmacotherapy of schizophrenia. Schizophrenia Bulletin 1983;9(4):533-42.
4. Carpenter WT, Heinrichs DW, Hanlon TE. A comparative trial of pharmacologic strategies in schizophrenia. American Journal of Psychiatry 1987;144(11):1466-70.
5. Carpenter WT, Hanlon TE, Heinrichs DW, Summerfelt A, Kirkpatrick B, Levine J, et al. Continuous vs. targeted medication in schizophrenic outpatients: Outcome results. American Journal of Psychiatry 1990;147:1138-48.
6. Carpenter WT, Stephens JH, Rey AC, Hanlon TE, Heinrichs DW. Early intervention vs continuous pharmacotherapy of schizophrenia. Psychopharmacology Bulletin 1982;18(1):21-3.
7. Gaebel W, Möller HJ, Buchkremer G, Ohmann C, Riesbeck M, Wölwer W, et al. Pharmacological long-term treatment strategies in first episode schizophrenia: study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 2004;254:129-40. [DOI: 10.1007/s00406-004-0509-y]
8. Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, Wilmsdorff M, et al. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomised controlled trial within the German Research Network on Schizophrenia. The Journal of Clinical Psychiatry 2007;68(11):1763-74.
9. Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, Wilmsdorff M, et al. Relapse prevention in first-episode schizophrenia - maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomised controlled trial within the German Research Network on Schizophrenia. Journal of Clinical Psychiatry February 2011;72(2):205-18.
10. Möller HJ, Riedel M, Jäger M, Wickelmaier F, Maier W, Kühn KU, et al. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. International Journal of Neuropsychopharmacology 2008;11(7):985-97.
11. Herz MI, Glazer W. Intermittent medication in schizophrenia - preliminary results. Schizophrenia Research 1988;1(2, 3):224-5.
12. Herz MI, Glazer W, Mirza M, Mostert M, Hafez H, Smith P, et al. Intermittent medication in schizophrenia: a preliminary report. In: Schulz SC, Tamminga CA editor(s). Schizophrenia: Scientific Progress. New York, USA: Oxford University Press, 1989:333-40.
13. Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV, Hafez H, et al. Intermittent vs maintenance medication in schizophrenia. Two-year results. Archives of General Psychiatry 1991;48(4):333-9. [MEDLINE: 1672588]
14. Herz MI, Szymanski HV, Simon JC. Intermittent medication for stable schizophrenic outpatients: an alternative to maintenance medication. American Journal of Psychiatry 1982;139:918-22. [MEDLINE: 6124133]
15. Hirsch SR, Jolley AG, Manchanda R, McRink A. Intermittent medication as an alternative to maintenance medication in the treatment of schizophrenia: a preliminary report [Fruehzeitige medikamentoese Intervention als Alternative zur Depot-Dauer-Medikation in der Schizophreniebehandlung Ein vorlaeufiger Bericht]. In: Boeker W, Brenner HD editor(s). Bewaltigung der Schizophrenie. Bern, Switzerland: Verlag Hans Huber, 1986:62-71.
16. Jolley AG, Hirsch SR. Intermittent and low-dosage neuroleptic treatment: preventive strategies in schizophrenia [Intermittierende und niedrigdosierte Neuroleptika-Therapie: Prophylaktische Strategien bei der Schizophrenie]. Therapie der Schizophrenie. UK: Kohlhammer, 1990:53-63.
17. Jolley AG, Hirsch SR, McRink A, Manchanda R. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ 1989;298(6679):985-90. [MEDLINE: 2567190]
18. Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ 1990;301(6756):837-42. [MEDLINE: 2567190]
19. McCreadie RG, Dingwall JM, Wiles DH, Heykants JJ. Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry 1980;137:510-7. [MEDLINE: 7011468]
20. McCreadie R, Mackie D, Morrison D, Kidd J. Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psyhciatry 1982;140:280-6.
21. Olson GW, Peterson DB. Intermittent chemotherapy for chronic psychiatric inpatients. Journal of Nervous and Mental Disease February 1962;134:145-9. [PUBMED: 14481933]
22. Bandelow B, Müller P, Frick U, Gaebel W, Linden M, Müller-Spahn F, et al. Depressive syndromes in schizophrenic patients under neuroleptic therapy. European Archives of Psychiatry and Clinical Neuroscience 1992;241(5):291-5. [MEDLINE: 1351405]
23. Gaebel W. Predictors of response to different neuroleptic long-term treatment strategies in schizophrenia. Schizophrenia Research 1995;15(1, 2):150. [MEDLINE: 241181]
24. Gaebel W, Frick U, Köpcke W, Linden M, Müller P, Müller-Spahn F, et al. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?. British Journal of Psychiatry Supplementum 1993;163(Suppl 21):8-12. [MEDLINE: 8105814]
25. Gaebel W, Janner M, Frommann N, Pietzcker A, Köpcke W, Linden M, et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophrenia Research 2002;53:145-59.
26. Godemann F, Linden M, Gaebel W, Köpcke W, Müller P, Müller-Spahn F, et al. Is interval medication a successful treatment regimen for schizophrenic patients with critical attitudes towards treatment?. European Psychiatry 2003;18:82-4. [DOI: 10.1016/S0924-9338(03)00008-7]
27. Müller P, Bandelow B, Gaebel W, Köpcke W, Linden M, Müller-Spahn F, et al. Intermittent medication, coping and psychotherapy: interactions in relapse prevention and course modification. British Journal of Psychiatry 1992;161(suppl. 18):140-4.
28. Pietzcker A. A German multi-centre study on the long-term treatment of schizophrenic outpatients. Pharmacopsychiat 1985;18:333-8.
29. Pietzcker A, Gaebel W, Köpcke W, Linden M, Müller P, Müller-Spahn F, et al. A German multicenter study on the neuroleptic long-term therapy of schizophrenic patients. Preliminary report. Pharmacopsychiatry 1986;19(4):161-6. [MEDLINE: 2868467]
30. Pietzcker A, Gaebel W, Köpcke W, Linden M, Müller P, Müller-Spahn F, et al. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia - 2-year results of a German multicenter study. Journal of Psychiatric Research 1993;27(4):321-39. [MEDLINE: 2868467]
31. Prien RF, Gillis RD, Caffey EM Jr. Intermittent pharmacotherapy in chronic schizophrenia. Hospital and Community Psychiatry 1973;24(5):317-22. [MEDLINE: 4574574]
32. Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. Journal of Clinical Psychiatry August 2011;72(8):1042-8.
33. Remington G, Seeman P, Shammi C, Mann S, Kapur S. "Extended" antipsychotic dosing: rationale and pilot data. Journal of Clinical Psychopharmacology 2005;25(6):611-3.
34. Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, et al. Relapse and rehospitalisation during maintenance treatment of schizophrenia. Archives of General Psychology 1997;54:453-63.
35. Goldberg SC, Shenoy RS, Sadler A, Hamer R, Ross B. The effects of a drug holiday on relapse and tardive dyskinesia in chronic schizophrenics. Psychopharmacology Bulletin 1981;17(1):116-7.
36. Shenoy RS, Sadler AG, Goldberg SC, Hamer RM, Ross B. Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. Journal of Clinical Psychopharmacology 1981;1(3):141-5. [MEDLINE: 6117584]
37. Wiedemann G, Hahlweg K, Müller U, Feinstein E, Hank G, Dose M. Effectiveness of targeted intervention and maintenance pharmacotherapy in conjunction with family intervention in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 2001;251:72-84.
38. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. Journal of Clinical Psychiatry May 2007;68(5):654-61.
39. Caffey EM, Prien RF. Practical considerations on treatment with antipsychotic preparations [Prakticheskie soobrazheniia o lechenii antipsikhoticheskimi preparatami]. Zhurnal Nevropatologii i Psikhiatrii Imeni S. S. Korsakova 1975;75(9):1399-401. [MEDLINE: 241181]
40. Docherty JP, Grogg AL, Pharm D, Kozma C, Lasser R. Antipsychotic maintenance in schizophrenia: partial compliance and clinical outcome. Presented at the International Congress on Schizophrenia Research Biennial Meeting. Colorado Springs, Colorado, US, March 29-April 2, 2003.
41. Engelhart LM, Janagap C, White RE. The implications of antipsychotic treatment patterns on health outcomes in schizophrenia. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002.
42. Engelhart LM, Janagap C, White RE, Rothman M. The implications of antipsychotic treatment patterns on health outcomes in schizophrenia. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA. 2000.
43. Hymowitz P, Spohn H. The effects of antipsychotic medication on the linguistic ability of schizophrenics. Journal of Nervous and Mental Disease 1980;168(5):287-96.
44. Levine J, Schooler N, Severe J, Escobar J, Gelenberg A, Mandel M, et al. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study. Advances in Biochemical Psychopharmacology 1980;24:483-93.
45. Newton JE, Cannon DJ, Couch L, Fody EP, McMillan DE, Metzer WS, et al. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients. Journal of Clinical Psychiatry 1989;50(4):132-5.
46. Strauss WH, Tegeler J, Luthcke H. Cognitive functions in schizophrenic patients under long-term neuroleptic therapy. Proceedings of the 17th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1990 Sep 10-14; Kyoto, Japan. 1990:304.
47. Uchida H, Mamo DC, Kapur S, Labelle A, Shammi C, Mannaert EJ, et al. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. Journal of Clinical Psychiatry 2008;69(8):1281-6. [PUBMED: 18642974]
48. Uchida H. D2 Receptor Blockade and Remission in Schizophrenia. UMIN-CTR Clinical Trial Registry, trial number UMIN000006011.
49. Altman DG, Bland JM. Detecing skewness from summary information. BMJ 1996;313:1200.
50. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Archives of General Psychiatry 1982;39(7):784-8.
51. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Vol. 3, Washington DC: American Psychiatric Association, 1980.
52. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Vol. 4, Washington DC: American Psychiatric Association, 1994.
53. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychosis. Archives of General Psychiatry 1988;45:79-91.
54. Barbui C, Saraceno B, Liberati A, Garattini S. Low-dose neuroleptic therapy and relapse in schizophrenia: meta-analysis of randomised controlled trials. European Psychiatry 1996;11:306-13.
55. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
56. Bleuler E. The prognosis of dementia praecox - schizophrenia group [Die Prognose der Dementia Praecox - Schizophreniegruppe]. Allgemeine Zeitschrift fur Psychiatrie 1908;65:436-64.
57. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
58. Borison RL, Diamond BI, Sinha D, Gupta RP, Prince Ajiboye PA. Clozapine withdrawal rebound psychosis. Psychopharmacology Bulletin 1998;24:260-3.
59. Carpenter WT, Heinrichs DW. Early intervention, time limited, targeted pharmacotherapy of schizophrenia. Schizophrenia Bulletin 1983;9(4):533-42.
60. Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
61. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine 2002;346:16-22.
62. Curson DA, Barnes TRE, Bamber RW, Platt SD, Hirsch SR, Duffy JC. Long term depot maintenance of chronic schizophrenic out-patients: the seven-year follow-up of the Medical Reseach Council fluphenazine/placebo trial. British Journal of Psychiatry 1985;146:464-80.
63. Davis JM. Recent developments in the drug treatment of schizophrenia. American Journal of Psychiatry 1976;133:208-14.
64. Day JC, Wood G, Dewey M, Bentall RP. A self-rating scale for measuring neuroleptic side-effects: validation in a group of schizophrenic patients. British Journal of Psychiatry 1995;166:650-3.
65. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
66. Dencker SJ, Lepp M, Malm U. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. Acta Psychiatrica Scandinavica Supplementum 1980;279:10-28.
67. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
68. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
69. Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
70. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
71. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale; A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 1976;33:766-71.
72. Feighner JP, Robins E, Guze SB, Woodruff RA, Winokur G, Munos R. Diagnostic criteria for the use in psychiatric research. Archives of General Psychiatry 1972;26:57-63.
73. Fleischhacker WW, Bergmann KJ, Perovich R, Pestreich LK, Borenstein M, Lieberman JA, et al. The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. Psychopharmacological Bulletin 1989;25(2):222-6.
74. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59:7-10.
75. Gaebel W, Janner M, Frommann N, Pietzcker A, Köpcke W, Linden M, et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophrenia Research 2002;53:145-59.
76. Gardos G, Cole J. Maintenance antipsychotic therapy: is the cure worse than the disease?. American Journal of Psychiatry 1976;133(1):32-6.
77. Gilbert PL, Harris J, McAdam LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients - a review of the literature. Archives of General Psychiatry 1995;52:173-88.
78. Gilbody S, House A, Sheldon T. Psychiatrists in the UK do not use outcomes measures: National Survey. British Journal of Psychiatry 2002;180:101-3.
79. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
80. Guy W, Bonato RR. Clinical Global Impressions. Manual for the ECDEU Assessment Battery. Vol. 2. Rev, National Institute of Mental Health, 1970:212-222.
81. Guy U. ECDEU Assessment Manual for Psychopharmacology. Revised. Rockville: National Institute of Mental Health, 1976.
82. Haddad P, Dursun S. Neurological complications of psychiatric drugs: clinical features and management. Human Psychopharmacology Clinical and Experimental 2008;23:15-26. [DOI: 10.1002/hup.918]
83. Hawk AB, Carpenter WT, Strauss JS. Diagnostic criteria and five-year outcome in schizophrenia: a report from the International Pilot Study of Schizophrenia. Archives of General Psychiatry 1975;32:343-7.
84. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984;10:388-98.
85. Herz MI, Melville C. Relapse in schizophrenia. American Journal of Psychiatry 1980;137:801-5.
86. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
87. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. Availabel from www.cochrane-handbook.org. Chichester, UK: John Wiley & Sons, Ltd, 2008.
88. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. The Cochrane Collaboration 2011; Vol. Available from www.cochrane-handbook.org.
89. Hutton Jane L. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
90. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: WHO, 1992.
91. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, et al. Schizophrenia: manifestations, incidence and course indifferent cultures. A World Health Organization ten-country study. Psychological Medicine (Monograph Supplement) 1992;20:1-97.
92. Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
93. Johnstone EC. Psychiatry, its history and boundaries. In: Johnstone EC, Freeman CPL, Zealley AK editor(s). Companion to Psychiatric Studies. Edinburgh: Churchill Livingstone, 1998:1-10.
94. Kane JM, Aguglia E, Carlo Altamura A, Guiterrez JLA, Brunello N, Fleischhacker WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology 1998;8:55-66.
95. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi-Health Systems, 1986.
96. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13(2):261-76.
97. Klein D, Davis JM. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, MD: Williams and Wilkins, 1969.
98. Kraepelin E. Textbook of Psychiatry [Lehrbuch der Psychiatrie]. Psychiatrie. Vol. 5, Erlangen: Ferdinand Enke, 1896.
99. Lambert TJ, Cock N, Alcock SJ, Kelly DL, Conley RR. Measurement of antipsychotic-induced side-effects: support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement. Human Psychopharmacology 2003;18(5):405-11.
100. Leff J, Wing J. Trial of maintenance therapy in schizophrenia. British Medical Journal 1971;3:559-604.
101. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale Scores. British Journal of Psychiatry 2005;187:366-71.
102. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
103. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
104. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209-23.
105. Marder SR, Wirshing DA. Maintenance treatment. In: Hirsch SR, Weinberger DR editor(s). Schizophrenia. 2nd Edition. Oxford: Blackwell, 2003.
106. Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;176:249-52.
107. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285(12):1987-91.
108. Morken G, Widen J, Grawe R. Non-adherence to antipsychotic medication, relapse and re-hospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008;8(1):32. [DOI: 10.1186/1471-244X-8-3]
109. Neuchterlein KH, Snyder KS, Dawson ME, Rappe S, Gitlin M, Fogelson D. Expressed emotion, fixed dose fluphenazine decanoate maintenance and relapse in recent onset schizophrenia. Psychopharamacology Bulletin 1986;22:633-9.
110. The NICE guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. National Clinical Guideline: 82. Updated edition. London, Leicester: The British Psychological Society and The Royal College of Psychiatrists, British Library, Stanley Hunt, 2010.
111. Nose M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychological Medicine 2003;33:1149-60.
112. O'Carroll RE, Smith K, Couston M, Cossar JA, Hayes PC. A comparison of the WHOQOL-100 and the WHOQOL-BREF in detecting change in quality of life following liver transplantation. Quality of Life Research 2000;9(1):121-4.
113. Oliver J. The social care directive: development of a quality of life profile for use in community services for the mentally ill. Social Work and Social Sciences Review 1991;3:5-45.
114. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
115. Perkins DO. Predictors of noncompliance in patients with schizophrenia. Journal of Clinical Psychiatry 2002;63:1121-8.
116. Prudo R, Blum HM. Five-year outcome and prognosis in schizophrenia. British Journal of Psychiatry 1987;150:345-54.
117. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. The New England Journal of Medicine 2009;360:225-35.
118. Spitzer RL, Endicott J, Robins E. Research Diagnostic Criteria (RDC) for a selected group of functional disorders. Biometrics Research. New York State Psychiatric Institute, 1978:0-33.
119. Schooler NR, Keith SJ. The clinical research base for the treatment of schizophrenia. Psychopharmacology Bulletin 1993;29:431-46.
120. Schooler N. Maintenance medication for schizophrenia: strategies for dose reduction. FOCUS Winter 2004;2(1):175-86.
121. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
122. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
123. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica et Neurologica Scandinavica, Supplementum 1970;212:11-9.
124. Spitzer RL, Endicott J. An integrated group of forms for automated psychiatric case records: a progress report. Archives of General Psychiatry 1971;24:448-53.
125. Thornley B, Adams CE. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998;317:1181-4.
126. TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ 2003;327(7417):708-13. [EMBASE: 2003210869]
127. Alexander J, Tharyan P, Adams CE, John T, Mol C, Philip J. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry 2004;185:63-9.
128. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92.
129. Scandinavian Society of Psychopharmacology Committee of Clinical Investigations. The UKU side-effect rating scale: scale for the registration of unwanted effects of psychotropics. Acta Psychiatrica Scandinavica 1987;76(suppl):81-94.
130. van Nieuwenhuizen C, Schene AH, Koeter MWJ, Huxley PJ. The Lancashire Quality of Life Profile: modification and psychometric evaluation. Social Psychiatry and Psychiatric Epidemiology 2001;36:36-44.
131. Weissman MM, Bothwell S. Assessment of Social Adjustment by patient self-report. Archives of General Psychiatry 1976;33(9):1111-5.
132. World Health Organisation. Pharmacological treatment of mental health disorders in primary health care. http://whqlibdoc.who.int/publications/2009/9789241547697_eng.pdf 2009:9-18.
133. Wiersma D, de Jong A, Kraaijkamp HJM, et al. The Groningen Social Disabilities Schedule, second version. The Groningen Social Disabilities Schedule, second version. Groningen, Netherlands: Department of Psychiatry, Rijksuniversiteit Groningen, 1990.
134. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
135. Mansour M, Alomar A, Boobes K, Mouchli MA. Intermittent drug techniques for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD006196]